Clinical development plan: genistein.
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000517:prevention & control*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017277:Drug Approval; D005260:Female; D019833:Genistein; D006801:Humans; D007529:Isoflavones / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D009374:Neoplasms, Experimental / Q000517:prevention & control; D011471:Prostatic Neoplasms / Q000517:prevention & control*; D051381:Rats; D012107:Research Design; D018675:Toxicity Tests
D016588:Anticarcinogenic Agents; D007529:Isoflavones; D019833:Genistein